000			05438nam a2200373Ia 4500
001			CRC0KE10649PDF
003			BD-DhSAU
005			20151012144304.0
006			m|||||o||d||||||||
007			cr||||
008			111202s2012 fluadf s 000 0 eng d
020			_a9781439813836 (ebook : PDF)
040			_aBD-DhSAU _cBD-DhSAU
090			_aRS431.A64 _bA562 2012
092			_a616.994061 _bA629
245	0	0	_aAnticancer agents from natural products _h[electronic resource] / _cedited by Gordon M. Cragg, David G.I. Kingston, David J. Newman.
250			_a2nd ed.
260			_aBoca Raton : _bCRC Press, _c2012.
300			_axv, 751 p., [16] p. of plates : _bill. (some col.).
505	0		_ach. 1. Introduction / Gordon M. Cragg, David G.I. Kingston, and David J. Newman -- ch. 2. Camptothecin and its analogs / Nicolas J. Rahier, Craig J. Thomas, and Sidney M. Hecht -- ch. 3. The discovery and development of the combretastatins / Kevin G. Pinney ... [et al.] -- ch. 4. Homoharringtonine and related compounds / Hideji Itokawa, Yukio Hitotsuyanagi, and Kuo-Hsiung Lee -- ch. 5. Podophyllotoxins and analogs / Kuo-Hsiung Lee and Zhiyan Xiao -- ch. 6. Taxol and its analogs / David G.I. Kingston -- ch. 7. The vinca alkaloids / Fanny Roussi, Fran�coise Gu�eritte, and Jacques Fahy -- ch. 8. The bryostatins / David J. Newman -- ch. 9. The isolation, characterization, and development of a novel class of potent antimitotic macrocyclic depsipeptides : the cryptophycins / Rima S. Al-awar and Chuan Shih -- ch. 10. Chemistry and biology of the discodermolides, potent mitotic spindle poisons / Sarath P. Gunasekera and Amy E. Wright -- ch. 11. The dolastatins : novel antitumor agents from Dolabella auricularia / Erik Flahive and Jayaram Srirangam -- ch. 12. Ecteinascidin-743 (Yondelis), Aplidin, and Irvalec / Carmen Cuevas ... [et al.] -- ch. 13. Discovery of E7389, a fully synthetic macrocyclic ketone analog of halichondrin B / Melvin J. Yu, Yoshito Kishi, and Bruce A. Littlefield --
505	8		_ach. 14. HTI-286 (Taltobulin), a synthetic analog of the antimitotic natural product hemiasterlin / Raymond J. Andersen ... [et al.] -- ch. 15. The actinomycins / Anthony B. Mauger and Helmut Lackner -- ch. 16. Anthracyclines / Federico-Maria Arcamone -- ch. 17. Ansamitocins (Maytansinoids) / Tin-Wein Yu ... [et al.] -- ch. 18. Benzoquinone ansamycins / Kenneth M. Snader -- ch. 19. Bleomycin group antitumor agents / Sidney M. Hecht -- ch. 20. Biochemical and biological evaluation of (+)-CC-1065 analogs and conjugates with polyamides / Rohtash Kumar and J. William Lown -- ch. 21. Epothilone, a myxobacterial metabolite with promising antitumor activity / Gerhard H�ofle and Hans Reichenbach -- ch. 22. Enediynes / Philip R. Hamann, Janis Upeslacis, and Donald B. Borders -- ch. 23. The mitomycins / William A. Remers -- ch. 24. Staurosporines and structurally related indolocarbazoles as antitumor agents / Michelle Prudhomme -- ch. 25. Combinatorial biosynthesis of anticancer natural products / Steven G. Van Lanen and Ben Shen -- ch. 26. Developments and future trends in anticancer natural products drug discovery / Gordon M. Cragg and David J. Newman.
520			_a"The search for new lead compounds is a crucial element of modern pharmaceutical research. Natural products provided the only source of pharmaceuticals for thousands of years, and natural products have made enormous contributions to human health through compounds such as quinine, morphine, aspirin (a natural product analog), digitoxin, and many others. The potential of natural products as anticancer agents was recognized in the 1950's by the U. S. National Cancer Institute (NCI) under the leadership of the late Dr. Jonathan Hartwell, and the NCI has since made major contributions to the discovery of new naturally occurring anticancer agents through its contract and grant support, including an important program of plant and marine collections. Many, although not all, of the compound classes described in the following pages owe their origin in whole or in part to NCI support. In spite of the success of the natural products approach to anticancer drug discovery, as exemplified by the following chapters, in recent years their importance as a source of molecular diversity for drug discovery research and development has been overshadowed by newer chemical approaches currently in favor. These approaches include chemical ones which make heavy use of combinatorial chemistry, and biological ones such as manipulation of biosynthetic pathways of microbial metabolites through combinatorial biosynthetic techniques. It is thus worthwhile to review briefly the major reasons why natural products are so important. First, there is a strong biological and ecological rationale for plants and marine invertebrates to produce novel bioactive secondary metabolites"-- _cProvided by publisher.
530			_aAlso available in print edition.
538			_aMode of access: World Wide Web.
650		0	_aAntineoplastic agents.
650		0	_aPharmacognosy.
650		0	_aNatural products.
655		7	_aElectronic books. _2lcsh
700	1		_aCragg, Gordon M. L.
700	1		_aKingston, David G. I.
700	1		_aNewman, David J.
776	1		_z9781439813829 (hardback)
856	4	0	_uhttp://marc.crcnetbase.com/isbn/9781439813836 _qapplication/PDF
999			_c11579 _d11578